The effect of the selective 5‐HT 1A agonists alnespirone (S‐20499) and 8‐OH‐DPAT on extracellular 5‐hydroxytryptamine in different regions of rat brain

1 We have examined the effects of the systemic administration of the selective 5‐HT 1A agonist alnespirone (S‐20499) on in vivo 5‐hydroxytryptamine (5‐HT) release in the dorsal raphe nucleus, the median raphe nucleus and four forebrain areas innervated differentially by both (dorsal striatum, frontal cortex, ventral hippocampus and dorsal hippocampus). 2 Alnespirone (0.1–3 mg kg −1 , s.c.) dose‐dependently reduced extracellular 5‐HT in the six areas examined. In forebrain, the maximal reductions occurred in striatum and frontal cortex (maximal reduction to 23 and 29% of baseline, respectively). Those in dorsal and ventral hippocampus were more moderate (to ca 65% of baseline). In contrast, the decrease in 5‐HT elicited in the median raphe nucleus was more marked than that in the dorsal raphe nucleus (to ca 30 and 60% of baseline, respectively). The selective 5‐HT 1A antagonist WAY‐100635 (0.5 mg kg −1 , s.c.) prevented the decrease in 5‐HT induced by alnespirone (0.3 mg kg −1 , s.c.) in frontal cortex. 3 8‐OH‐DPAT (0.025, 0.1 and 0.3 mg kg −1 , s.c.) also reduced extracellular 5‐HT in a regionally‐selective manner (e.g., to 32% of baseline in striatum and to 69% in dorsal hippocampus at 0.1 mg kg −1 , s.c.). In midbrain, 8‐OH‐DPAT reduced the dialysate 5‐HT slightly more in the median than in the dorsal raphe nucleus at all doses examined. 4 Doses of both compounds close to their respective ED 50 values (0.3 mg kg −1 alnespirone, 0.025 mg kg −1 8‐OH‐DPAT) reduced 5‐HT to a comparable extent in all regions examined. However, the reductions attained at higher doses were more pronounced for 8‐OH‐DPAT. 5 These data show that the reduction of 5‐HT release elicited by alnespirone and 8‐OH‐DPAT is more important in forebrain areas innervated by 5‐hydroxytryptaminergic neurones of the dorsal raphe nucleus. This regional selectivity seems unlikely to be accounted for by differences in the sensitivity of 5‐HT 1A autoreceptors controlling 5‐HT release, given the dissimilar effects of these two 5‐HT 1A agonists in regions rich in cell bodies and nerve terminals. This suggests the presence of complex mechanisms of control of 5‐HT release by 5‐HT 1A receptors.British Journal of Pharmacology (1997) 122 , 733–741; doi: 10.1038/sj.bjp.0701420